Vote Scores

Home / Companies / Viking Therapeutics, Inc.

Company · votes reported on Form N-PXVKTX · SEC company no. 1607678

Viking Therapeutics, Inc.

How funds and institutional managers reported voting their shares, year to 30 June 2026

Filers reporting
533year to 30 June 2026
Against management on pay
40.4%197 of 488 reporting filers
Same, by reported shares
24.6%shares reported on Form N-PX
Meetings on file
3across 3 seasons
54.3% for38.3% against7.4% other40.4% against management525 filers on say-on-pay

foragainstabstain, withhold or otheramber tick: the portion cast against management

533 Form N-PX filers reported votes at Viking Therapeutics, Inc. for the year to 30 June 2026, across 2 meetings.

On the advisory vote on executive pay, 197 of the 488 filers that reported a position voted against management (40.4%), 33.8 percentage points above the median company on this site (6.6%). By reported shares the figure is 24.6% (median 2.9%). These are shares of the filers reporting on Form N-PX, not of all votes cast at the meeting.

Meetings

Meeting dateSeasonFilers reportingItemsAgainst management on pay
19 May 2026year to 30 June 2026529440.4%
20 May 2025year to 30 June 2025527342.2%
21 May 2024year to 30 June 2024513511.2%

Meetings with 20 or more reporting filers have their own page with every item. Dates are as filers typed them; dates up to three days apart are treated as one meeting.

Say-on-pay: this company and the median

year to 30 June 2026Viking Therapeutics, Inc.Median company
Reporting filers voting against management40.4%6.6%
Reported shares voted against management24.6%2.9%

Among filers reporting on Form N-PX. The median is over 3,799 companies with a say-on-pay item reported by 20 or more filers.

How the largest families voted

Meeting of 19 May 2026: say-on-pay and each shareholder proposal that could be told apart.

FamilySay-on-pay
VanguardFor
BlackRock and iSharesAgainst *
FidelityFor
DimensionalAgainst *
State Street and SPDRFor
American CenturyAgainst *
Franklin TempletonAgainst *
InvescoAgainst *
EquitableAgainst *
Charles SchwabFor
Nuveen and TIAAFor
ProShares and ProFundsAgainst *
John Hancock and ManulifeAgainst *
Morgan Stanley, Eaton Vance and CalvertAgainst *
J.P. MorganFor
Goldman SachsFor
WisdomTreeFor
PGIM and PrudentialAgainst *
Jackson National fundsAgainst *
Northern Trust and FlexSharesAgainst *
SEIFor
T. Rowe PriceAgainst *
Lincoln FinancialAgainst
VoyaFor
First TrustAgainst *
Russell InvestmentsFor
Victory CapitalAgainst *
Guggenheim and RydexAgainst *
Columbia ThreadneedleAgainst *
BNY MellonAgainst *
PrincipalFor
Pacific Life fundsAgainst *
AllianceBernsteinAgainst *
DWSAgainst *
AllspringSplit or no vote
MassMutualFor
Harbor FundsFor
Macquarie and Delaware FundsAgainst *
Neuberger BermanFor
Natixis and Loomis SaylesFor
BairdFor

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

By season

SeasonFilers reportingAgainst management on pay, filersBy reported sharesSay-on-pay split
year to 30 June 202451511.2%6.0%
year to 30 June 202553242.2%28.3%
year to 30 June 202653340.4%24.6%

Category mix

Share of the vote records reported for this company, by the category filers chose.

CategoryVote recordsShare
SECTION 14A SAY-ON-PAY VOTES2,24140.1%
DIRECTOR ELECTIONS1,75631.5%
AUDIT-RELATED87815.7%
COMPENSATION66111.8%
CAPITAL STRUCTURE460.8%

Questions

How did large funds vote at Viking Therapeutics, Inc.?

For the year to 30 June 2026, 488 Form N-PX filers reported a say-on-pay vote at Viking Therapeutics, Inc.; 197 voted against management (40.4%). The table on this page lists the position of each of the largest fund families on say-on-pay and on each shareholder proposal that could be told apart in the filings.

Were there shareholder proposals at Viking Therapeutics, Inc.?

No proposal from security holders was reported by enough filers to be shown for the year to 30 June 2026.

Is this the meeting result?

No. The figures are shares of the funds and managers that file Form N-PX, and of the shares they reported. Holders that do not file the form (individuals, most foreign investors, insiders) are not included, so the split here can differ widely from the certified result, which Viking Therapeutics, Inc. reports on Form 8-K.

Where does the data come from?

From Form N-PX filings on the SEC's EDGAR system, grouped by company. Filers type company names and meeting dates themselves; this site groups spellings of the same company and folds meeting dates up to three days apart. Data runs through 23 Sep 2026; the median compares 3,799 companies.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Viking Therapeutics, Inc., grouped by company. The name is the most common spelling among filers; the ticker and SEC company number come from the SEC company tickers file, matched on the exact name. Not verified by the SEC. Filings read through 23 Sep 2026; page built 26 Sep 2026.